Valneva's Lyme Vaccine Passes First Regulatory Gate — But the Half-Year Numbers Demand a Reality Check
Published on 08/15/2026 at 17:42 | Redaktion boerse-global.de
The market chose to focus on the future on Friday, and the past will have to wait. Valneva's shares jumped 27 percent to €3.06 after the European Medicines Agency formally accepted the marketing application for PF-07307405, the Lyme disease vaccine candidate developed in partnership with Pfizer. That single regulatory validation was enough to eclipse a set of half-year results that showed losses widening to €63.3 million.
The disconnect between the stock's reaction and the underlying financials is stark. Product revenue fell to €64 million from €91 million in the same period last year, while the operating loss nearly tripled to €49.9 million. Adjusted EBITDA swung from minus €6.0 million to minus €40.1 million. Even IXIARO, the company's core revenue driver, came under pressure: delayed deliveries to the US Department of Defense and a distribution switch in Germany dragged sales down to €44 million.
Third-party distribution revenue collapsed by 91.6 percent to just €1 million — a deliberate wind-down of a legacy business, but also a clear illustration of how radically Valneva is reshaping itself. The company is selling off its headquarters in Nantes for €6.2 million, a deal expected to close in September, and has launched a global restructuring that will cut 10 to 15 percent of the workforce and reduce operating costs by 25 to 35 percent.
Cash stood at €121.5 million at the end of June, slightly above year-end levels and including €34.3 million raised in a second-quarter capital increase. That gives the company breathing room, but little more. Management has reaffirmed its full-year guidance of €135 million to €150 million in product sales and €145 million to €160 million in total revenue for 2026.
Should investors sell immediately? Or is it worth buying Valneva?
The real story behind Friday's rally is the pipeline, not the P&L. The EMA's validation of PF-07307405 is a procedural milestone, but a meaningful one: it rests on Phase 3 efficacy of over 70 percent in preventing Lyme disease in people aged five and older, demonstrated in the VALOR study. Regulatory decisions are expected within the next twelve months, with Europe likely to move first.
Stifel analyst Damien Choplain called the EMA validation a "significant de-risking event" and reiterated a Buy rating with a €7.50 price target on Thursday. The logic is straightforward: the most obvious existential risk — regulatory rejection — has just receded. Days earlier, TD Cowen's Tara Bancroft had initiated coverage with a Buy and a $12 price target, estimating peak sales of around €3.1 billion by 2035, which could translate into roughly €590 million in licensing revenue for Valneva.
TD Cowen has since gone further, upgrading the stock to "Strong Buy" on August 11. The Friday jump extends a recovery that has already seen the shares climb 39 percent over the past 30 days. But that momentum carries the hallmarks of a heated move, and the real tests lie ahead: the EMA's review itself and, for the third quarter of 2026, Phase 2 data on the Shigella vaccine candidate in infants plus results from a controlled human challenge study.
The Chikungunya vaccine IXCHIQ offers at least some evidence that the platform can deliver, with roughly 50,000 doses administered in a Brazilian pilot program. But until the regulatory verdict on PF-07307405 lands, the Lyme candidate remains a promise rather than a revenue stream. Investors who rode Friday's rally should remember that the re-rating hinges on a process whose outcome no one can predict — and that the company's present-day accounts tell a far more sober story.
Ad
Valneva Stock: New Analysis - 15 August
Fresh Valneva information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
